Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?
- Praxis Precision Medicines and Remagine Labs recently entered a research collaboration and license agreement to develop an iontophoretic transdermal patch for ulixacaltamide, complementing Praxis’s oral program in essential tremor and supported by Praxis’s equity investment in Remagine.
- This new transdermal delivery route for ulixacaltamide, together with the FDA’s three‑month extension of relutrigine’s NDA review without new trial requirements, could reshape how investors view the reach and durability of Praxis’s pipeline.
- We’ll now examine how the Remagine Labs transdermal patch collaboration could influence Praxis’s existing investment narrative around its CNS portfolio.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
Praxis Precision Medicines Investment Narrative Recap
To own Praxis, you have to believe its central nervous system pipeline can move from promising data to approved products in epilepsy, developmental encephalopathies and essential tremor. In the near term, the key catalyst remains the FDA review of relutrigine’s NDA, while the biggest risk is that late stage trials or regulatory reviews do not convert into approvals. The Remagine Labs patch collaboration and FDA’s three month relutrigine review extension both feed directly into that near term story.
Among recent developments, the change of auditor from Ernst & Young to KPMG stands out beside the Remagine Labs agreement. While it does not alter the core clinical catalysts, investors often track auditor transitions closely as part of assessing financial reporting quality and execution discipline, especially for a company with no current product revenue and a heavy reliance on external capital to fund its CNS pipeline.
Yet, even as the pipeline broadens, investors should also be aware that...
Read the full narrative on Praxis Precision Medicines (it's free!)
Praxis Precision Medicines’ narrative projects $1.4 billion revenue and $434.2 million earnings by 2029. This implies an earnings increase of about $760.7 million from -$326.5 million today.
Uncover how Praxis Precision Medicines' forecasts yield a $617.67 fair value, a 94% upside to its current price.
Exploring Other Perspectives
Before this patch news, the most optimistic analysts were penciling in revenue of about US$2.1 billion and earnings near US$783.6 million by 2029, while also assuming Praxis could fund multiple large epilepsy programs without straining its cash runway, which is a far more optimistic view than the baseline and may be revisited as the new ulixacaltamide delivery route and related capital needs come into clearer focus.
Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth over 9x more than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.
No Opportunity In Praxis Precision Medicines?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Find 47 companies with promising cash flow potential yet trading below their fair value.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com